Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.53 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694618 | 1.00 | GNPAT (0.58) | GNPATMMEALPIPKMPTGS1 | |
| SCHEMBL93439 | 1.00 | GNPAT (0.58) | GNPATMMEALPIPKMPTGS1 | |
| SCHEMBL412958 | 1.00 | GNPAT (0.58) | GNPATMMEALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL27197703 | 0.98 | GNPAT (0.57) | GNPATMMEALPIPKMPTGS1 | |
| Oxalic Acid SCHEMBL8649953 | 0.96 | GNPAT (0.56) | GNPATMMEALPIPKMPTGS1 | |
| Malonic Acid SCHEMBL8644619 | 0.94 | GNPAT (0.55) | GNPATMMEALPIPKMPTGS1 | |
| Formic Acid SCHEMBL30065163 | 0.93 | GNPAT (0.53) | GNPATMMEALPIPKMPTGS1 | |
| Succinic Acid SCHEMBL8643183 | 0.93 | NAALAD2 (0.60) | GNPATMMEALPIPKMPTGS1 | |
| Succinic Acid SCHEMBL8645926 | 0.93 | NAALAD2 (0.60) | GNPATMMEALPIPKMPTGS1 | |
| Maleic Acid SCHEMBL8645722 | 0.91 | SLC15A1 (0.54) | GNPATMMEALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081503-B1 | A PROCESS FOR THE SYNTHESIS OF MELPHALAN | INDENA SPA (IT) | 2025-07-30 | — | — | EP | claimed |
| CN-119776360-A | GPIHBP1 mutant gene and application thereof | 中国人民解放军东部战区总医院 | 2025-04-08 | — | — | CN | claimed |
| US-20240124910-A1 | RIBOSOME-MEDIATED POLYMERIZATION OF NOVEL CHEMISTRIES | NORTHWESTERN UNIVERSITY | 2024-04-18 | — | — | US | claimed |
| CN-117384912-A | GPIHBP1 mutant gene and application thereof | 中国人民解放军东部战区总医院 | 2024-01-12 | — | — | CN | claimed |
| US-11787761-B2 | Process for the synthesis of Melphalan | INDENA S.P.A. (IT) | 2023-10-17 | — | — | US | claimed |
| WO-2023151679-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | SHENZHEN ENDURING BIOTECH , LTD. (CN) | 2023-08-17 | — | — | WO | claimed |
| WO-2023147365-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING PROTEIN NANOWIRES WITH TUNABLE FUNCTIONALITY | YALE UNIVERSITY (US) | 2023-08-03 | — | — | WO | claimed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| WO-2023102077-A1 | ANTI-FOLATE RECEPTOR CONJUGATE CANCER THERAPY | SUTRO BIOPHARMA, INC. (US) | 2023-06-08 | — | — | WO | claimed |
| US-20230094970-A1 | A PROCESS FOR THE SYNTHESIS OF MELPHALAN | INDENA S.P.A. (IT) | 2023-03-30 | — | — | US | claimed |
| WO-2004103304-A2 | TREATMENT OF T-CELL MEDIATED DISEASES | DMI BIOSCIENCES, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| EP-1439210-A1 | NON-NATURAL LABELED AMINO ACID AND METHOD OF CONSTRUCTING AMINO ACID/tRNA COMPLEX | Protein Express Co., Ltd. (JP) | 2004-07-21 | — | — | EP | claimed |
| EP-1423515-A1 | ANTI-AGING AND WOUND HEALING COMPOUNDS | Kimberly-Clark Worldwide, Inc. (US) | 2004-06-02 | — | — | EP | claimed |
| WO-2003018748-A2 | ANTI-CANCER AND WOUND HEALING COMPOUNDS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-03-06 | — | — | WO | claimed |
| WO-2003016520-A1 | ANTI-AGING AND WOUND HEALING COMPOUNDS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| EP-0973801-B1 | GnRH ANTAGONISTS | FERRING BV (NL) | 2002-12-18 | — | — | EP | claimed |
| WO-2002085923-A2 | IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-10-31 | — | — | WO | claimed |
| US-6077680-A | INHIBITING KV1 POTASSIUM CHANNEL ACTIVITY IN A LYMPHOCYTE OF AN ANIMAL BY ADMINISTERING POLYPEPTIDE OF SPECIFIC AMINO ACID SEQUENCE; FOR TREATMENT OF AUTOIMMUNE DISORDERS | THE UNIVERSITY OF FLORIDA (US) | 2000-06-20 | — | — | US | claimed |
| EP-0833654-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO THE IL-1 RECEPTOR | Affymax Technologies N.V. (GB) | 1998-04-08 | — | — | EP | claimed |
| WO-1996039165-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO THE IL-1 RECEPTOR | AFFYMAX TECHNOLOGIES N.V. (GB) | 1996-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094970-A1 | A PROCESS FOR THE SYNTHESIS OF MELPHALAN | PAH, IL4I1, TYR | GNPAT 762/4885MME 59/4885ALPI 4038/4885 |
| US-11787761-B2 | Process for the synthesis of Melphalan | PAH, TYR, MARS1 | GNPAT 851/4885MME 61/4885ALPI 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.